Use of Yescarta in Acute Lymphoblastic Leukemia Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute lymphoblastic leukemia (r/r ALL). ALL is …
CAR T-Cell Therapy HCP Guide – Use of Yescarta in Acute Lymphoblastic Leukemia Read More
October 17, 2017 (Medical News Today) Scientists and researchers from the UK have set out to investigate why cancer often returns in patients whose cancers have become dormant, focusing especially …
Cancer recurrence may be stopped with immunotherapy Read More
While side effects can be challenging, the fact remains that complete and partial remissions are impressive with CAR T-cell therapy. All eligible patients have exhausted their cancer treatment options, and …
CAR T-Cell Therapy HCP Guide – What Studies Are Ongoing With CAR T-Cell Therapy? Read More
CAR T-Cell FDA Approval: Status Update In addition to the approval of Kymriah, Yescarta (axicabtagene ciloleucel or Axi-Cel) was approved on October 18, 2017 for the treatment of adult patients …
CAR T-Cell Therapy HCP Guide – Updates from the FDA Read More
September 6, 2017 (HealthDay News) In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy Outcomes of treatment with third-generation CAR T-cell therapy in CD19-positive B-cell malignancy are associated with …
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy Read More
July 31, 2017 (Medical News Today) A lack of understanding of molecular mechanisms which let cancer cells escape detection from the immune system is a reason why existing chemotherapy and …
Cell mechanism discovery could lead to ‘fundamental’ change in leukemia treatment Read More
July 19, 2017 (Medical News Today) Following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy, researchers presented that 70 percent of patients with the most common adult leukemia had tumor …
CAR T-cell therapy for leukemia leads to remissions in clinical trial Read More
July 1, 2017 (Medical News Today) The cancer drug, rituximab, is not a chemotherapy, but a monoclonal antibody therapy that uses antibodies which stick to specific cells or proteins and …
Human antibody bolsters cancer drug performance Read More
September 8, 2016 (HealthDay News) Researchers identify treatment characteristics that correlate with therapeutic response, toxicity Immunotherapy with CD19 chimeric antigen receptor (CAR)-modified T cells in a defined CD4+/CD8+ ratio can …
Remission Up With T Cell Therapy for Non-Hodgkin’s Lymphoma Read More
July 3, 2017 (Medical News Today) Overall, the immune system does a remarkable job defending the body from disease-causing agents. When it comes to cancer, however, it falls short. Niroshana …
New insights into why the immune system fails to see cancer Read More